Take home message:
What would I like to see on the follow up of this paper?
The application of [11C]CPPC targeting CSF1R in neuroinflammation-linked diseases has great potential for clinical translation. Currently, the inaccuracy of diagnosis and treatment for neurodegenerative diseases is a great matter of discussion. In AD, it seems that neuroinflammatory changes may emerge even earlier than detectable canonical Aβ and tau pathology. If [11C]CPPC could detect this initial neuroinflammatory alterations with topographical resolution could help to detect the earliest AD-related changes, opening a new window for therapeutic intervention.